Skip to main content
Home logo

User account menu

Log inSearch

Main navigation

  • Home
  • Data Sources
  • Studies
  • Institutions
  • Networks
  • What's new
  • Support
  1. Home

Subscribe to TAK-660-403: Evaluation of Long-term Safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, Rurioctocog Alfa Pegol) in Patients With Haemophilia A - An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS) (TAK-660-403: ADYNOVI/ADYNOVATE PASS)

HMA-EMA Catalogues of real-world data sources and studies

Privacy

Privacy policy
Cookies
Legal notice

Contact

Contact us